Carmot Therapeutics Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 70

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $3.3B

Carmot Therapeutics General Information

Description

Carmot Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people living with metabolic diseases including obesity and diabetes. It has three clinical-stage product candidates are: CT-388, a once-weekly subcutaneous injectable, dual GLP-1/GIP receptor agonist for the treatment of obesity and type 2 diabetes (T2D); CT-996, a once-daily oral, small molecule GLP-1 receptor agonist for the treatment of obesity and T2D; and CT-868, a once-daily subcutaneous injectable, dual GLP-1/GIP receptor agonist for the treatment of type 1 diabetes (T1D) patients with overweight or obesity.

Contact Information

Website
www.carmot.us
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • 740 Heinz Avenue
  • Berkeley, CA 94710
  • United States
+1 (888)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Parent Company
Vertical(s)
Corporate Office
  • 740 Heinz Avenue
  • Berkeley, CA 94710
  • United States
+1 (888)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Carmot Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Merger/Acquisition 26-Jan-2024 $3.3B Completed Clinical Trials - Phase 2
10. IPO 17-Nov-2023 Cancelled Clinical Trials - Phase 2
9. Later Stage VC (Series E) 25-May-2023 Completed Clinical Trials - Phase 2
8. Later Stage VC (Series D) 25-Jul-2022 Completed Clinical Trials - Phase 2
7. Later Stage VC (Series C) 30-Sep-2020 Completed Clinical Trials - Phase 2
6. Debt - PPP 03-May-2020 Completed Clinical Trials - Phase 2
5. Later Stage VC (Series B) 17-Jan-2018 Completed Pre-Clinical Trials
4. Early Stage VC (Series A) 17-Jul-2012 Completed Startup
3. Grant 08-Dec-2011 $300K $300K Completed Startup
2. Grant 31-Dec-2010 $440K $300K Completed Startup
To view Carmot Therapeutics’s complete valuation and funding history, request access »

Carmot Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series E
Series D1
Series D
Series C
Series B 1,977,878 $0.001000 $0.51 $6.37 $6.37 1x $6.37 3.64%
Series A 3,431,745 $0.001000 $0.05 $0.63 $0.63 1x $0.63 6.32%
To view Carmot Therapeutics’s complete cap table history, request access »

Carmot Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Carmot Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for
Biotechnology
Berkeley, CA
70 As of 2023

Calimera, Italy
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Carmot Therapeutics Competitors (1)

One of Carmot Therapeutics’s competitors is Gelesis, a Formerly VC-backed company based in Calimera, Italy.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Gelesis Formerly VC-backed Calimera, Italy
You’re viewing 1 of 1 competitors. Get the full list »

Carmot Therapeutics Patents

Carmot Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026213480-A1 Gpcr receptor agonists, pharmaceutical compositions comprising the same, and methods for their use Pending 04-Apr-2025
US-20260137758-A1 Treatment of steatotic liver disease associated with metabolic dysfunction Pending 20-Nov-2024
WO-2026112366-A1 Treatment of steatotic liver disease associated with metabolic dysfunction Pending 20-Nov-2024
WO-2026112366-A9 Treatment of steatotic liver disease associated with metabolic dysfunction Pending 20-Nov-2024
WO-2026073030-A1 Combination therapy of peptide tyrosine-tyrosine (pyy) analogues and glp-1r agonists Pending 27-Sep-2024 A61K38/26
To view Carmot Therapeutics’s complete patent history, request access »

Carmot Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Carmot Therapeutics Former Investors (19)

Investor Name Investor Type Holding Investor Since Participating Rounds
5AM Ventures Venture Capital Minority
Amgen Corporation Minority
Deep Track Capital Venture Capital Minority
Franklin Templeton Asset Manager Minority
Frazier Healthcare Partners PE/Buyout Minority
You’re viewing 5 of 19 investors. Get the full list »

Carmot Therapeutics FAQs

  • When was Carmot Therapeutics founded?

    Carmot Therapeutics was founded in 2008.

  • Where is Carmot Therapeutics headquartered?

    Carmot Therapeutics is headquartered in Berkeley, CA.

  • What is the size of Carmot Therapeutics?

    Carmot Therapeutics has 70 total employees.

  • What industry is Carmot Therapeutics in?

    Carmot Therapeutics’s primary industry is Biotechnology.

  • Is Carmot Therapeutics a private or public company?

    Carmot Therapeutics is a Private company.

  • What is the current valuation of Carmot Therapeutics?

    The current valuation of Carmot Therapeutics is .

  • What is Carmot Therapeutics’s current revenue?

    The current revenue for Carmot Therapeutics is .

  • How much funding has Carmot Therapeutics raised over time?

    Carmot Therapeutics has raised $374M.

  • Who are Carmot Therapeutics’s investors?

    5AM Ventures, Amgen, Deep Track Capital, Franklin Templeton, and Frazier Healthcare Partners are 5 of 19 investors who have invested in Carmot Therapeutics.

  • Who are Carmot Therapeutics’s competitors?

    Gelesis is a competitor of Carmot Therapeutics.

  • When was Carmot Therapeutics acquired?

    Carmot Therapeutics was acquired on 26-Jan-2024.

  • Who acquired Carmot Therapeutics?

    Carmot Therapeutics was acquired by Roche.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process